Glenmark Pharmaceuticals set to begin clinical trial of GRC 54276 in US
Glenmark Pharmaceuticals, through its subsidiary Glenmark Specialty, is set to begin a first-in-human, phase 1/2 clinical study of GRC 54276 in the US for the treatment of advanced solid tumors and lymphomas. This was after Glenmark Specialty’s investigational new drug (IND) application for GRC 54276 was accepted by the US Food and Drug Administration (FDA). […]